Clarkston Capital Partners’s AbbVie ABBV Stock Holding History

Clarkston Capital Partners’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-2,700	Closed	-$617K	–	99
2025 Q4	$617K	Hold	2,700	–	–	0.01%	133
2025 Q3	$625K	Hold	2,700	–	–	0.01%	128
2025 Q2	$501K	Hold	2,700	–	–	0.01%	126
2025 Q1	$566K	Sell	2,700 -400	-13%	-$77.8K	0.01%	114
2024 Q4	$551K	Sell	3,100 -250	-7%	-$46K	0.01%	117
2024 Q3	$662K	Hold	3,350	–	–	0.01%	112
2024 Q2	$575K	Hold	3,350	–	–	0.01%	116
2024 Q1	$610K	Hold	3,350	–	–	0.01%	113
2023 Q4	$519K	Hold	3,350	–	–	0.01%	111
2023 Q3	$499K	Hold	3,350	–	–	0.01%	116
2023 Q2	$451K	Hold	3,350	–	–	0.01%	118
2023 Q1	$534K	Sell	3,350 -300	-8%	-$45.9K	0.01%	111
2022 Q4	$590K	Hold	3,650	–	–	0.01%	110
2022 Q3	$490K	Buy	3,650 +50	+1%	+$7.17K	0.01%	120
2022 Q2	$551K	Hold	3,600	–	–	0.01%	120
2022 Q1	$584K	Hold	3,600	–	–	0.01%	126
2021 Q4	$487K	Hold	3,600	–	–	0.01%	121
2021 Q3	$388K	Hold	3,600	–	–	0.01%	113
2021 Q2	$406K	Hold	3,600	–	–	0.01%	114
2021 Q1	$390K	Buy	+3,600	New	+$385K	0.01%	114

Other funds holding ABBV

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Clarkston Capital Partners's ABBV Position: Q1 2026 in Review

Clarkston Capital Partners sold out of AbbVie (ABBV) in Q1 2026, closing a stake of 2,700 shares — an estimated $617K sold.

Clarkston Capital Partners first reported a position in ABBV in Q1 2021 and held it in 20 quarters. The position peaked at $662K in Q3 2024. 4,080 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.

Clarkston Capital Partners reported no remaining AbbVie position as of Q1 2026 after selling out during the quarter.
Clarkston Capital Partners sold 2,700 AbbVie shares in Q1 2026, an estimated $617K.
Clarkston Capital Partners first reported a position in AbbVie in Q1 2021 and held it in 20 quarters.
Clarkston Capital Partners's AbbVie position peaked at $662K in Q3 2024.
4,080 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.

Based on Clarkston Capital Partners's 13F filing for Q1 2026, filed 14 May 2026.